Category: LinkedIn

FDA INTERNATIONAL INSPECTION APPROACH- PART II

Quality and Laboratory System In my earlier post, I described the techniques and approaches that are currently being used to inspect international firms who are importing products to USA or Europe. Continuing with my original format I will try to compare the different methodologies used by FDA and EU inspectors to conduct Quality and Laboratory […]

Continue Reading

FDA INTERNATIONAL INSPECTION APPROACH- PART 1

FDA Responsibility –  Is there inspectional approach differences for International companies by FDA ? Most can agree that regulating the safety and effectiveness of drugs and medical devices is for the protection of public health and we applaud the regulatory agencies who work tirelessly to make this possible. Our company has participated in many inspections with our […]

Continue Reading

Why 10 Lots are Important

10 Lot Dilema The core to establishing analytical similarity is creating a statistically valid package that shows the reference product is statistically the same as the biosimilar candidate. In order to evidence and show analytical characterization FDA recommends a three tier approach which requires the procurement and comparative testing of at least 10 lots of […]

Continue Reading

FDA Friend or FOE for Biosimilar Companies

Role of Agency – Protect Patient Safety The FDA is mandated to regulate that drugs that are approved are safe and efficacious and do not posed any risk to patient health. Biosimilars have a slight different starting point since most of the molecules have been shown to be safe and effective for decades. Why does […]

Continue Reading